CN1041416C - N-乙酰基神经氨酸衍生物的合成 - Google Patents

N-乙酰基神经氨酸衍生物的合成 Download PDF

Info

Publication number
CN1041416C
CN1041416C CN93118291A CN93118291A CN1041416C CN 1041416 C CN1041416 C CN 1041416C CN 93118291 A CN93118291 A CN 93118291A CN 93118291 A CN93118291 A CN 93118291A CN 1041416 C CN1041416 C CN 1041416C
Authority
CN
China
Prior art keywords
acid
formula
compound
glyceryl
ninth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CN93118291A
Other languages
English (en)
Other versions
CN1099389A (zh
Inventor
V·帕特尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biotech Science Management Co., Ltd.
Original Assignee
Biota Scientific Management Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biota Scientific Management Pty Ltd filed Critical Biota Scientific Management Pty Ltd
Publication of CN1099389A publication Critical patent/CN1099389A/zh
Application granted granted Critical
Publication of CN1041416C publication Critical patent/CN1041416C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D309/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Abstract

5-乙酰氨基-2,3,4,5-四脱氧-4-胍基-D-甘油基-D-半乳糖-壬-2-烯醇-吡喃糖酸的制备方法,它包括在水性介质中将5-乙酰氨基-2,3,4,5-四脱氧-4-氨基-D-甘油基-D-半乳糖-壬-2-烯醇-吡喃糖酸与吡唑-1H-羧酰胺或其衍生物反应。

Description

N-乙酰基神经氨酸衍生物的合成
本发明涉及N-乙酰基神经氨酸衍生物的制备方法。具体地说,本发明涉及5-乙酰氨基-2,3,4,5-四脱氧-4-胍基-D-甘油基-D-半乳糖-壬-2-烯醇-吡喃糖酸(DANA的4-胍基类似物;也称为5-(乙酰氨基)-2,6-脱水-4-胍基-D-甘油基-D-乳壬-2-烯酸)及其衍生物的制备方法。
PCT/AU9I/00161(公开号WO91/16320)描述了多种包括DANA的4-胍基类似物在内的5-乙酰氨基-2,3,5-三脱氧-D-甘油基-D-半乳糖-壬-2-烯醇-吡喃糖酸(2,3-二脱氧-2,3-二脱水-N-乙酰基-神经氨酸;DANA)衍生物。DANA的4-胍基类似物是通过将对应的O-酰基保护的DANA的4-氨基类似物与S-甲基异脲反应,随后去保护而制得的。
我们现在发现了直接从未保护的DANA的4-氨基类似物制备DANA的4-胍基类似物的方法。
DANA的4-氨基和4-胍基类似物结构如下:
DANA的4-氨基类似物                      DANA的4-胍基类似物
因此,首先本发明提供5-乙酰氨基-2,3,4,5-四脱氧-4-胍基-D-甘油基-D-半乳糖-壬-2-烯醇-吡喃糖酸的制备方法,它包括将5-乙酰氨基-4-氨基-2,3,4,5-四脱氧-D-甘油基-D-半乳糖-壬-2-烯醇-吡喃糖酸与式(I)化合物反应,式(I)如下:
Figure C9311829100051
式中X1,X2,X3和X4至少有一个是C-R,其余为C-R或N;各R可相同或不同并且是H、C1-6烷基、未取代或取代的苯基、未取代或取代的苯基C1-4烷基或吸电子基团。
在式(I)化合物中,当R是吸电子基团时,可以使用任何这样的基团。这样的基团是本领域技术人员所熟知的,例如羧基、硝基和氰基。
式(I)化合物可以游离碱或酸加成盐的形式使用。适宜的盐包括从下列无机或有机酸衍生而来的盐:例如盐酸、氢溴酸、硫酸、硝酸、过氯酸、富马酸、马来酸、磷酸、乙醇酸、乳酸、水杨酸、琥珀酸、甲苯对苯磺酸、酒石酸、乙酸、柠檬酸、甲磺酸、甲酸、苯甲酸、丙二酸、萘-2-磺酸和苯磺酸。
优选的式(I)化合物是吡唑环上带有一个C1-6烷基的吡唑-1H-羧酰胺。
特别优选的式(I)化合物是游离碱或者最好是酸加成盐形式的吡唑-1H-羧酰胺,例如吡唑-1H-羧酰胺盐酸盐(PCH)。
该反应可方便地在水性介质中进行。所谓水性介质是指包括大量(例如≥50%)水的任何液体介质。优选仅含水的水性介质。
该反应可在室温或高温如30-70℃下进行。该反应最好在约50-55℃进行。
在反应中,DANA的4-氨基类似物与所用的式(I)化合物的摩尔比可以是约1∶1到1∶10,例如1∶1到1∶3,式(I)化合物最好摩尔过量约1.5-2倍,例如约1.8倍。
反应在约pH6-9的范围内进行。在反应过程中pH可在此范围内变化。
当式(I)化合物以酸加成盐的形式使用时,可通过加入一种或多种无机或有机碱而使pH值保持在期望的范围内。这样的碱包括例如碱金属氢氧化物和碳酸盐,例如氢氧化锂、碳酸钠或碳酸氢钠;和胺类,例如三乙胺、咪唑或1,8-二氮二环[5.4.0]十一-7-烯(DBU)。保持期望pH所需的碱的量取决于具体所用的碱。控制pH所需的碱的量对于本领域专业人员来说是显而易见的。
可以用任何常规方法从反应混合物中分离所需的DANA的4-胍基类似物,例如用结晶或层析的方法。尤其是可用下述方法分离DANA的4-胍基类似物:即用与水不相溶的并且不能溶解该化合物的有机溶剂处理水性溶液。这样的溶剂包括例如脂肪醇(如甲醇和异丙醇(IPA))和丙酮。
下述实施例仅用来进一步说明本发明,不应该理解为对本发明的限定。
                        实施例1
5-乙酰氨基-2,3,4,5-四脱氧-4-胍基-D-
甘油基-D-半乳糖-壬-2-烯醇-吡喃糖酸
将5-乙酰氨基-4-氨基-2,3,4,5-四脱氧-D-甘油基-D-半乳糖-壬-2-烯醇-吡喃糖酸三水合物(58.05g;169mmol)的水(300ml)溶液在33℃下搅拌,再一次加入吡唑-1H-羧酰胺盐酸盐(600mmol,87.95g),随后加入三乙胺(60ml,pH=8.4),搅拌5小时。
将此反应混合物粗品加入高速搅拌的甲醇(900ml)中。继续搅拌过夜,收集沉淀固体,用4∶1甲醇/水(250ml)洗涤,空气干燥,于42℃的真空烘箱干燥2小时。产量=46.7g。
将如此制得的产物(45.5g)悬浮于水(518ml)中,高速搅拌的同时加热。将所得溶液迅速过滤,自然冷却至室温。将溶液进一步冷却(冰-水浴)至3℃,用1小时的时间向该冷溶液中滴加异丙醇(450ml),继续搅拌1.5小时以上。滤出沉淀固体,于40℃干燥,得到与真实样本相同的标题化合物(30.49g)。
                  实施例2
5-乙酰氨基-2,3,4,5-四脱氧-4-胍基-D-甘油基-D-半乳糖-壬-2-烯醇-吡喃糖酸
将5-乙酰氨基-4-氨基-2,3,4,5-四脱氧-D-甘油基-D-半乳糖-壬-2-烯醇-吡喃糖酸三水合物(15.0g)、吡唑-1H-羧酰胺盐酸盐(7.55g)和咪唑(11.55g)与水(52.5ml)的混合物于50-55℃加热搅拌。18小时后,用丙酮(150ml)处理所得浆液15分钟,同时保持容器内物料温度为50-55℃。然后将混合物冷却至15-20℃,再过3小时,真空滤集产物。滤饼依次用4∶1丙酮/水(2×25ml)和丙酮(25ml)洗涤。产物在室温空气干燥,得标题化合物(10.98g)。PMR(D2O)  2.04(3H,s),3.67 (2H,m),3.93(2H,m),4.23(1H,m),4.42(2H,m)
      5.63(1H,d,J2.5Hz)IR(Nujol) 3428,3338,3253:NH,OH
      1692,1666,1646,1619,1575;CO(CH3CONH,CO2),CN.

Claims (13)

1. 5-乙酰氨基-2,3,4,5-四脱氧-4-胍基-D-甘油基-D-半乳糖-壬-2-烯醇-吡喃糖酸的制备方法,它包括将5-乙酰氨基-4-氨基-2,3,4,5-四脱氧-D-甘油基-D-半乳糖-壬-2-烯醇-吡喃糖酸与式(I)化合物反应,式(I)如下:式中X1,X2,X3和X4至少有一个是C-R,其余为C-R或N;各R可相同或不同并且是H、C1-6烷基、未取代或取代的苯基、未取代或取代的苯基C1-4烷基或吸电子基团。
2.根据权利要求1的方法,其中式(I)化合物是吡唑-1H-羧酰胺或其在吡唑环上带有C1-6烷基的衍生物。
3.根据权利要求2的方法,其中式(I)化合物是吡唑-1H-羧酰胺。
4.根据权利要求1的方法,其中式(I)化合物是酸加成盐的形式。
5.根据权利要求4的方法,其中所述盐是盐酸盐。
6.根据权利要求1的方法,其中反应是在水性介质中进行的。
7.根据权利要求6的方法,其中水性介质是水。
8.根据权利要求1的方法,其中该过程是在30-70℃的温度下进行的。
9.根据权利要求8的方法,其中的温度是50-55℃。
10.根据权利要求1的方法,其中的pH值是在6-9的范围内。
11.根据权利要求1-9中任一项的方法,其中5-乙酰氨基-2,3,4,5-四脱氧-4-氨基-D-甘油基-D-半乳糖-壬-2-烯醇-吡喃糖酸与式(I)化合物的摩尔比是在1∶1到1∶10的范围内。
12.根据权利要求11的方法,其中摩尔比是约1∶1.8。
13.根据权利要求11的方法,其中pH值是在6-9的范围内。
CN93118291A 1992-09-25 1993-09-24 N-乙酰基神经氨酸衍生物的合成 Expired - Lifetime CN1041416C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9220327.2 1992-09-25
GB929220327A GB9220327D0 (en) 1992-09-25 1992-09-25 Process

Publications (2)

Publication Number Publication Date
CN1099389A CN1099389A (zh) 1995-03-01
CN1041416C true CN1041416C (zh) 1998-12-30

Family

ID=10722539

Family Applications (1)

Application Number Title Priority Date Filing Date
CN93118291A Expired - Lifetime CN1041416C (zh) 1992-09-25 1993-09-24 N-乙酰基神经氨酸衍生物的合成

Country Status (21)

Country Link
EP (1) EP0662967B1 (zh)
CN (1) CN1041416C (zh)
AT (1) ATE162188T1 (zh)
AU (1) AU672634B2 (zh)
CA (1) CA2144342C (zh)
CY (1) CY2110B1 (zh)
DE (1) DE69316382T2 (zh)
DK (1) DK0662967T3 (zh)
ES (1) ES2112433T3 (zh)
FI (1) FI112224B (zh)
GB (1) GB9220327D0 (zh)
GR (1) GR3026298T3 (zh)
IL (1) IL107069A (zh)
IS (1) IS4071A (zh)
MX (1) MX9305902A (zh)
NO (1) NO308743B1 (zh)
PL (1) PL174446B1 (zh)
SG (1) SG50642A1 (zh)
TW (1) TW282464B (zh)
WO (1) WO1994007886A1 (zh)
ZA (1) ZA937032B (zh)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5866601A (en) * 1995-02-27 1999-02-02 Gilead Sciences, Inc. Carbocyclic compounds
HU228450B1 (en) 1995-02-27 2013-03-28 Gilead Sciences Inc Novel selective inhibitors of viral or bacterial neuraminidases
US5763483A (en) * 1995-12-29 1998-06-09 Gilead Sciences, Inc. Carbocyclic compounds
US5859284A (en) * 1996-08-23 1999-01-12 Gilead Sciences, Inc. Preparation of carbocyclic compounds
US6518438B2 (en) 1996-08-23 2003-02-11 Gilead Sciences, Inc. Preparation of cyclohexene carboxylate derivatives
US5994377A (en) * 1996-10-21 1999-11-30 Gilead Sciences, Inc. Piperidine compounds
US5886213A (en) * 1997-08-22 1999-03-23 Gilead Sciences, Inc. Preparation of carbocyclic compounds
TW477783B (en) * 1997-12-12 2002-03-01 Gilead Sciences Inc Novel compounds useful as neuraminidase inhibitors and pharmaceutical compositions containing same
DE10230780A1 (de) * 2002-07-09 2004-02-05 Degussa Ag Verfahren zur Herstellung von 1-Methylcyclopropylguanidin bzw. dessen Salzen
KR20110098760A (ko) 2008-11-28 2011-09-01 시플라 리미티드 자나미비르의 제조방법 및 상기 제조방법에 사용되는 중간체
EP2678324A1 (en) 2011-02-24 2014-01-01 Cadila Healthcare Limited Process for the preparation of zanamivir

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991016320A1 (en) * 1990-04-24 1991-10-31 Biota Scientific Management Pty Ltd Derivatives and analogues of 2-deoxy-2,3-didehydro-n-acetyl neuraminic acid and their use as antiviral agents

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU659501B2 (en) * 1991-10-23 1995-05-18 Biota Scientific Management Pty Ltd Antiviral 4-substituted-2-deoxy-2,3-didehydro-derivatives of alpha-D-neuraminic acid
GB9126725D0 (en) * 1991-12-17 1992-02-12 Glaxo Group Ltd Process

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991016320A1 (en) * 1990-04-24 1991-10-31 Biota Scientific Management Pty Ltd Derivatives and analogues of 2-deoxy-2,3-didehydro-n-acetyl neuraminic acid and their use as antiviral agents

Also Published As

Publication number Publication date
NO308743B1 (no) 2000-10-23
CY2110B1 (en) 2002-04-26
MX9305902A (es) 1994-05-31
SG50642A1 (en) 1999-04-27
NO951136D0 (no) 1995-03-24
ZA937032B (en) 1994-05-16
NO951136L (no) 1995-05-08
PL174446B1 (pl) 1998-07-31
AU672634B2 (en) 1996-10-10
ES2112433T3 (es) 1998-04-01
IL107069A (en) 1998-01-04
IL107069A0 (en) 1993-12-28
WO1994007886A1 (en) 1994-04-14
FI112224B (fi) 2003-11-14
FI951378A0 (fi) 1995-03-23
PL308203A1 (en) 1995-07-24
EP0662967A1 (en) 1995-07-19
GB9220327D0 (en) 1992-11-11
AU5108893A (en) 1994-04-26
EP0662967B1 (en) 1998-01-14
CA2144342A1 (en) 1994-04-14
IS4071A (is) 1994-03-26
CA2144342C (en) 2000-05-16
CN1099389A (zh) 1995-03-01
DE69316382T2 (de) 1998-07-23
TW282464B (zh) 1996-08-01
DE69316382D1 (de) 1998-02-19
FI951378A (fi) 1995-03-23
DK0662967T3 (da) 1998-09-14
GR3026298T3 (en) 1998-06-30
ATE162188T1 (de) 1998-01-15

Similar Documents

Publication Publication Date Title
CN1041416C (zh) N-乙酰基神经氨酸衍生物的合成
CN113135882A (zh) 一种一锅法合成玻色因的方法
CN1061343C (zh) 制备n-乙酰神经氨酸衍生物的方法
US6022965A (en) Method for isomerising the 10-methyl radical of erythromycin derivatives
CN1149222C (zh) 糠酸莫米松的制备方法
JP3771128B2 (ja) フェブリフジンおよびフェブリフジン化合物の新規合成方法
CN109678853A (zh) 一种达沙替尼的制备工艺
JP2002167521A (ja) ジヒドロペリミジンスクエア化合物の製造方法
EP0994888B1 (en) Process for the acylation of amino alcohols
JPH05238990A (ja) 1,4,5,8−テトラキス(ヒドロキシメチル)ナフタレン誘導体およびその製造方法
CN86105582A (zh) 1,1′-亚氨基-二(八亚甲基)-双胍3-烷基苯磺酸盐的制备方法
EP1652837A1 (en) Aminocarbonyl naphthol derivative, cyanonaphthol derivative, and method for producing them
CN112409420B (zh) 一种2’-氟-2’-脱氧尿苷的纯化方法
KR970001536B1 (ko) 트리요오도벤젠 유도체의 제조방법
CN1136195C (zh) 3-烃基-5-吡唑羧酸酯的合成方法
CN1148376C (zh) 克林霉素-2-磷酸苄酯的制备方法
CN1025494C (zh) 一种2,2,3,3-四甲基环丙烷羧酸的制备
CN1680316A (zh) 一种酰亚胺基不饱和酮的制备方法
JPS6144856A (ja) フエニルアセトアルデヒド誘導体
SU1227633A1 (ru) Способ получени производных имидазо [4,5- @ ] индолов
CN109134296A (zh) 一种肼基乙酸乙酯盐酸盐的合成方法
US4084057A (en) Process for the production of 4-acylamido-4, 4-dicarbalkoxy-butanalphenylhydrazone
CN111978254A (zh) 一种阿替美唑盐酸盐的制备工艺
JPH1084990A (ja) 光学活性2,4,4−トリメチル−2−シクロヘキセン−1−オール及びそのエステル類の製造方法
JPH0812635A (ja) アシルアミノフタル酸誘導体の製造方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C53 Correction of patent of invention or patent application
COR Change of bibliographic data

Free format text: CORRECT: APPLICANT; FROM: GLAXO GROUP LIMITED TO: BIOTA SCIENT MAN

CP03 Change of name, title or address

Address after: Vitoria, Australia

Applicant after: Biotech Science Management Co., Ltd.

Address before: England

Applicant before: GLAXO Group Ltd.

C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CX01 Expiry of patent term

Expiration termination date: 20130924

Granted publication date: 19981230